Purpose The aim of this study was to investigate factors associated with the occurrence of extrapyramidal symptoms (EPS) in users of second-generation antipsychotics (SGA). Methods Observational cross-sectional study based on a random sample of subjects from three outpatient clinics. Inclusion criteria were age between 18 and 65 years, of both genders, with a diagnosis of schizophrenia and under the use of a single SGA agent. Subjects who had received i.m. longacting antipsychotics in the past were excluded. The families of eligible patients were contacted by phone and, if willing to participate in the study, a household visit was scheduled. Informed consent was obtained from all study subjects and their next of kin. The risk of EPS associated with sociodemographic, clinical features and medications used was analyzed by logistic regression.
Introduction
Schizophrenia is a severe and persistent mental disorder characterized by distortions of thinking and perception, inadequacy and blunting of affect, and cognitive impairment with disease progression [1] . This mental disorder affects about 1% of the world population [2] . In Brazil, patients with schizophrenia represent 30% of all occupants of psychiatric wards and rank second place in outpatient psychiatric consultations, corresponding to 14% of all attendants [3] .
Antipsychotic drugs are the treatment of choice for schizophrenia. They are classified as conventional, or firstgeneration antipsychotics (FGA), and atypical, or second-generation antipsychotics (SGA). They drastically reduce psychotic symptoms and efficiently prevent new crises [4] . The FGA, who were developed initially, commonly present serious adverse reactions, with relevance to extrapyramidal symptoms (EPS), e.g., muscle stiffness, akathisia, tremors, and tardive dyskinesia (a neurological syndrome involving involuntary movements in the extremities such as fingers, toes, or the orofacial region) [5] . Since 1990, SGA have been developed in order to offer a more favorable safety profile. Initially, many studies have highlighted the greater safety of atypical compared to traditional antipsychotics, especially in relation to a lower incidence of EPS [6] . However, some authors have questioned those findings as a result of several identified methodological flaws, especially the tendency to use high doses of conventional antipsychotics in those studies [7] . Another pharmacological approach, which is still controversial in the treatment of schizophrenia, is the use of antipsychotics associated with other drug classes such as antidepressants, mood stabilizers (e.g., lithium, valproate, and carbamazepine), and benzodiazepines [8] , as there is limited evidence regarding the benefits of adjunctive therapy to antipsychotics [9] .
Thus, there is a serious difficulty in establishing the best approach to the drug treatment of schizophrenia, especially regarding the safety profile and the occurrence of EPS. Factors associated with the occurrence of extrapyramidal adverse events in SGA users are poorly documented, although they can affect the quality of life of patients with schizophrenia [10] .
Therefore, the objective of this study was to investigate the association of EPS with patient demographic, socioeconomic, and clinical features and with the administration of adjunctive drugs in patients with schizophrenia treated with SGA.
Methods

Study design and population
This was an observational, cross-sectional study performed during 15 months between 2013 and 2014 in psychiatric outpatient clinics in the State of Rio Grande do Norte, northeastern Brazil. Mental health institutions that participated were located in different cities with over 60,000 inhabitants. A convenience sample of three clinics was selected from a universe consisting of a total of 25 psychiatric outpatients clinics. Within each clinic, a simple random sample of subjects was taken using the numbers of the clinical records, with the same number of patients being selected at each institution. Of 252 patients who agreed to participate, 213 completed the study.
Inclusion criteria were age between 18 and 65 years old, both genders, with a diagnosis of schizophrenia (F20 to F20.9) according to the International Statistical Classification of Diseases and Related Health Problems (ICD-10), under the use of a single SGA agent and who agreed to participate in the study by signing an informed consent form, as well as their next of kin or caregiver. Subjects were excluded if they had used injectable long-acting antipsychotic agents in the past.
Data collection
The families of eligible patients were contacted by phone and, if they were willing to participate in the study, a household visit was scheduled. The following data were collected: gender, age, educational level, family income and participation in school and/or work activities, and use of atypical antipsychotic drugs and of other psychoactive drugs.
In order to improve the quality of data collection, a second interview was conducted on average 30 days after the first. We verified the continuity in the use of the same atypical antipsychotic and other prescription drugs in the period. Patients who discontinued any drug, went into psychosis, and/or had changed the antipsychotic drug were removed from the study.
To evaluate the occurrence of extrapyramidal symptoms, we used the Simpson-Angus Scale (SAS), an instrument consisting of ten items: one item measuring gait (hypokinesia), six items measuring rigidity, and three items measuring glabella tap, tremor, and salivation. The scale is scored by averaging the individual items. We considered patients with extrapyramidal manifestations those patients who achieved values greater than 0.3 in the SAS [11] [12] [13] . Prestudy sessions with the research team members in charge of applying the SAS were organized and a pilot study in ten patients was conducted under supervision of the authors.
Statistical analysis
Statistical analysis was performed using Stata release 11 (Stata Corporation, College Station, TX, USA). In the descriptive analysis, demographic, clinical, and economic variables were presented as absolute and relative frequencies, or by means and standard deviations, as appropriate. Logistic regression analysis was used to determine which variables considered in this study are associated with the occurrence of EPS. Variables with p < 0.10 in univariate analysis were included in a multivariate logistic regression model and associations were considered significant when p < 0.05. Results are presented as adjusted odds ratios (AOR) with 95% confidence intervals (CI). A sample size of about 220 subjects would afford 80% power to identify SGA drugs associated with EPS with an OR of 2.0 or greater and 70% power to identify SGA with an OR of 1.8 or greater, assuming an overall prevalence of EPS of 40% and a significance level of 5%.
Results
Two hundred and sixty-one patients were invited to the study. In nine cases (3.4%), the family declined participation and six had received i.m. long-acting antipsychotics in the past. Among the 246 included patients, 33 (13.4%) did not complete the study (4 withdrew consent, 29 could not be located for the second interview). There were no significant differences between participants and those who declined. The sociodemographic and clinical characteristics of the study population (213 subjects) are shown in Table 1 . The mean age was 39.7 ± 12.2 years, 39.4% were females, family income was low in average (US$ 364.2 ± 281.2), and educational level was very low (59.0% with only elementary school and the remaining illiterate). Few patients (19.6%) had access to any work activity or education.
A score higher than 0.3 on the Simpson-Angus Scale, indicating some degree of extrapyramidal manifestations, was observed in 81 patients (38.0%, 95% confidence interval 31.5 to 44.9%). The most often administered SGA agents were olanzapine (76 patients, 35.7%) and risperidone (73 patients, 34.3%), followed by quetiapine (26 patients, 12.2%), ziprasidone (23 patients, 10.8%), and clozapine (13 patients, 6.1%). Benzodiazepines predominated among the drugs used as adjunctive therapy of schizophrenia (67 patients, 31.5%). Derivatives of carbamide were slightly less used (52 patients, 24.4%) with carbamazepine being the sole used agent in this class. Antidepressants were also administered (13.6% selective serotonin re-uptake inhibitors (SSRI) and 6.6% tricyclic as well as lithium (9.4%)).
Univariate analysis ( The result of multiple logistic regression analysis (Table 3) showed that the risk of EPS increases with the use of carbamazepine (adjusted odds ratio 3.677, 95% CI 1.627-8.310) and possibly with the use of clozapine and fatty acids 
Discussion
Only a few studies have investigated factors associated with EPS in SGA users. Several methodological aspects contribute to the validity of our results: the study population was based on a random sample of patients, the refusal rate was very low, EPS was evaluated with a validated instrument, and the data were obtained directly at home by trained personnel. Data collection within the security of the household is important for the conduct of research on patients with schizophrenia. Our data showed no difference between the type of SGA and the manifestation of extrapyramidal symptoms, but some degree of EPS was observed in almost 40% of the sample. Patients who used carbamazepine as adjuvant to the schizophrenia treatment were more prone to present EPS, which is main finding of our study.
The EPS induced by antipsychotics is caused by inhibition of the nigrostriatal dopaminergic pathway through blockade of D2 receptors in the striatum [14] . SGA agents are characterized by a lower induction of EPS compared to classical antipsychotics [15] , and the low EPS manifestation associated with the SGA can be attributed to lower affinity for D2 receptors associated with the activation of 5HT2A serotoninergic receptors [14] .
Just under half of the sample had some degree of EPS and we found no relationship between the symptoms and the type of SGA. The effectiveness of an antipsychotic cannot be dissociated from its safety profile, since the better tolerability of SGAs has direct impact on the improvement of symptoms and adherence [16] . Certainly, the treatment of schizophrenia without EPS would be a major therapeutic breakthrough, but nowadays, it is clear that all SGA are prone to some degree of EPS, as observed in this study. Indeed, the incidence of clinical manifestations of EPS is still significant among SGA users, although to a lesser extent in most cases akathisia may occur in as much as 25% or more of the users, parkinsonism has a similar incidence as FGA with high doses of risperidone, quetiapine, and olanzapine, and even the feared tardive dyskinesia can also occur with the use of atypical antipsychotics [14] . Thus, it is clear that the risk of EPS still represents an important factor to be considered even among users of SGA.
The use of antipsychotics associated with mood stabilizer drugs is a common practice in treating schizophrenia. Carbamazepine administration has been a widespread strategy in the treatment of schizophrenic patients with resistant remission of their symptoms [17] . This product was introduced in 1963 as an effective anticonvulsant for the treatment of epilepsy and is currently used in the therapy of aggressive symptoms associated with schizoaffective disorder and schizophrenia [18] . The exact mechanism of action by which carbamazepine may act to control aggressive symptoms is not well understood, but it is believed that its direct psychotropic effects can stabilize structures that regulate emotions [17] [18] [19] .
If one considers only randomized clinical trials comparing the use of antipsychotics versus antipsychotics + carbamazepine, the literature is scarce in the investigation of the effectiveness and safety of this combination in the treatment of schizophrenia. Only two studies, to our knowledge, recommend the use of carbamazepine + FGA [20, 21] . However, the number of patients studied was considerably small. Moreover, other authors have shown that adjuvant therapy with carbamazepine does not produce better results in the reduction of psychotic symptoms [8] . The occurrence of EPS caused by carbamazepine in the adjuvant treatment of schizophrenia is inconclusive. Its use has been associated with disorders of movement in one study, but as only 20 subjects were evaluated this prevents further conclusions [22] . Carbamazepine when administered with haloperidol leads to lower incidence of EPS [23] . This is explained by a reduction in serum levels of haloperidol because of enzyme induction, but only with this FGA. The relationship between carbamazepine and EPS has been reported only in patients treated with FGA and, to our knowledge, the description of EPS associated with the use of carbamazepine in schizophrenia treated with SGA has not been published yet. Monotherapy with carbamazepine can cause motor disorders common to the EPS spectrum. For example, dystonia and asterixis are commonly caused by high doses of carbamazepine. The mechanism involved in movement disorders caused by carbamazepine is still unknown, but it suggests a relationship with increased GABAergic activity in the basal ganglia [24] . The main limitations of our study are the small sample size and the cross-sectional design. The locations chosen for the study have the characteristics of an underpriviledged community, with low average income per household and low education level with a significant percentage of illiteracy. The particular social and economic characteristics of the studied population may reduce the scope of possible generalizations of our results, but they are nevertheless a new finding in the study of EPS occurrence associated with SGA. In the future, to better characterize the relationship between EPS and carbamazepine, our group intends to conduct longitudinal studies with a larger numbers of participants.
Conclusions
In summary, the occurrence of EPS in SGA users is a common finding, with no difference of antipsychotics studied in relation to the risk of extrapyramidal manifestations. However, the adjunctive use of carboxamide derivatives, especially carbamazepine, may predispose the user of atypical antipsychotics to the occurrence of EPS.
Compliance with ethical standards The study was approved by the Ethics Committee for Research of the University Hospital Onofre Lopes under the number 207/09. The study complied with the Declaration of Helsinki of the World Medical Association. On the first visit after phone contact, all participants and the next of kin or caregiver signed an informed consent before any data was collected.
